Review



oxycodone hcl teva, oral immediate release  (Teva)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Teva oxycodone hcl teva, oral immediate release
    Description of the subjects in the clinical study.
    Oxycodone Hcl Teva, Oral Immediate Release, supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oxycodone+hcl+teva%2C+oral+immediate+release/pmc11748063-127-29-34?v=Teva
    Average 90 stars, based on 1 article reviews
    oxycodone hcl teva, oral immediate release - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers"

    Article Title: Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers

    Journal: Frontiers in Neuroscience

    doi: 10.3389/fnins.2024.1492246

    Description of the subjects in the clinical study.
    Figure Legend Snippet: Description of the subjects in the clinical study.

    Techniques Used: Cannabis

    Identified differences in key features between baseline (sober) and drug conditions at peak plasma concentration and 5 h post-administration, under two ambient lighting conditions.
    Figure Legend Snippet: Identified differences in key features between baseline (sober) and drug conditions at peak plasma concentration and 5 h post-administration, under two ambient lighting conditions.

    Techniques Used: Clinical Proteomics, Concentration Assay

    Score vector of principal components 2 plotted vs. 1. The analysis is based on all key features collected at both light conditions. Data is from 48 subjects: 12 subjects across 4 types of drug families including baseline measurements and 5–6 subsequent assessments during 1–5 h after drug administration on the day of intake. Data points originating from the time point with highest average eye reaction magnitude are shown as large size markers. In some cases, subjects failed to produce data at this time point due to intoxication, leading to fewer than 12 large size markers in some cases. Green square = opioid (oxycodone). Purple triangle = phenethylamine (lisdexamphetamine). Blue diamond = benzodiazepine (lorazepam). Red circles = cannabis (Bedrocan). Black oval = drug sober baseline (95% of collected data inside the oval).
    Figure Legend Snippet: Score vector of principal components 2 plotted vs. 1. The analysis is based on all key features collected at both light conditions. Data is from 48 subjects: 12 subjects across 4 types of drug families including baseline measurements and 5–6 subsequent assessments during 1–5 h after drug administration on the day of intake. Data points originating from the time point with highest average eye reaction magnitude are shown as large size markers. In some cases, subjects failed to produce data at this time point due to intoxication, leading to fewer than 12 large size markers in some cases. Green square = opioid (oxycodone). Purple triangle = phenethylamine (lisdexamphetamine). Blue diamond = benzodiazepine (lorazepam). Red circles = cannabis (Bedrocan). Black oval = drug sober baseline (95% of collected data inside the oval).

    Techniques Used: Plasmid Preparation, Cannabis

    (A,B) Plasma concentration of oxycodone and dexamphetamine over time ( n = 12 subjects) and the key feature values for Dbase (z-transformed, from PLR) at sober baseline and 1, 2, 3, 4, and 5 h after drug administration. Ambient illumination was ~50 lux in a and 500 Lux in (B) . (C) Blood concentration of lorazepam over time ( n = 12 subjects) and key feature values for NCdiff (z-transformed, from NC, 50 Lux). (D) Blood concentration of THC over time ( n = 12 subjects) and the key feature values for MCA (z-transformed, from PLR, 50 lux).
    Figure Legend Snippet: (A,B) Plasma concentration of oxycodone and dexamphetamine over time ( n = 12 subjects) and the key feature values for Dbase (z-transformed, from PLR) at sober baseline and 1, 2, 3, 4, and 5 h after drug administration. Ambient illumination was ~50 lux in a and 500 Lux in (B) . (C) Blood concentration of lorazepam over time ( n = 12 subjects) and key feature values for NCdiff (z-transformed, from NC, 50 Lux). (D) Blood concentration of THC over time ( n = 12 subjects) and the key feature values for MCA (z-transformed, from PLR, 50 lux).

    Techniques Used: Clinical Proteomics, Concentration Assay, Transformation Assay



    Similar Products

    oxycodone hcl teva, oral immediate release  (Teva)
    90
    Teva oxycodone hcl teva, oral immediate release
    Description of the subjects in the clinical study.
    Oxycodone Hcl Teva, Oral Immediate Release, supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oxycodone+hcl+teva%2C+oral+immediate+release/pmc11748063-127-29-34?v=Teva
    Average 90 stars, based on 1 article reviews
    oxycodone hcl teva, oral immediate release - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Description of the subjects in the clinical study.

    Journal: Frontiers in Neuroscience

    Article Title: Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers

    doi: 10.3389/fnins.2024.1492246

    Figure Lengend Snippet: Description of the subjects in the clinical study.

    Article Snippet: Next, subjects visited the research unit after fasting for at least 6 h. During this visit, subjects were administered drugs in the form of one of four medicinal products: oxycodone (20 mg oxycodone HCl Teva, oral immediate release), lisdexamphetamine (70 mg Elvanse, oral), lorazepam (2.0 mg Lorazepam Aurobindo, oral) or medicinal cannabis [Bedrocan, Bedrocan International B.V., 65 mg with 22% THC (14.3 mg of which ~5 mg are bioavailable)].

    Techniques: Cannabis

    Identified differences in key features between baseline (sober) and drug conditions at peak plasma concentration and 5 h post-administration, under two ambient lighting conditions.

    Journal: Frontiers in Neuroscience

    Article Title: Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers

    doi: 10.3389/fnins.2024.1492246

    Figure Lengend Snippet: Identified differences in key features between baseline (sober) and drug conditions at peak plasma concentration and 5 h post-administration, under two ambient lighting conditions.

    Article Snippet: Next, subjects visited the research unit after fasting for at least 6 h. During this visit, subjects were administered drugs in the form of one of four medicinal products: oxycodone (20 mg oxycodone HCl Teva, oral immediate release), lisdexamphetamine (70 mg Elvanse, oral), lorazepam (2.0 mg Lorazepam Aurobindo, oral) or medicinal cannabis [Bedrocan, Bedrocan International B.V., 65 mg with 22% THC (14.3 mg of which ~5 mg are bioavailable)].

    Techniques: Clinical Proteomics, Concentration Assay

    Score vector of principal components 2 plotted vs. 1. The analysis is based on all key features collected at both light conditions. Data is from 48 subjects: 12 subjects across 4 types of drug families including baseline measurements and 5–6 subsequent assessments during 1–5 h after drug administration on the day of intake. Data points originating from the time point with highest average eye reaction magnitude are shown as large size markers. In some cases, subjects failed to produce data at this time point due to intoxication, leading to fewer than 12 large size markers in some cases. Green square = opioid (oxycodone). Purple triangle = phenethylamine (lisdexamphetamine). Blue diamond = benzodiazepine (lorazepam). Red circles = cannabis (Bedrocan). Black oval = drug sober baseline (95% of collected data inside the oval).

    Journal: Frontiers in Neuroscience

    Article Title: Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers

    doi: 10.3389/fnins.2024.1492246

    Figure Lengend Snippet: Score vector of principal components 2 plotted vs. 1. The analysis is based on all key features collected at both light conditions. Data is from 48 subjects: 12 subjects across 4 types of drug families including baseline measurements and 5–6 subsequent assessments during 1–5 h after drug administration on the day of intake. Data points originating from the time point with highest average eye reaction magnitude are shown as large size markers. In some cases, subjects failed to produce data at this time point due to intoxication, leading to fewer than 12 large size markers in some cases. Green square = opioid (oxycodone). Purple triangle = phenethylamine (lisdexamphetamine). Blue diamond = benzodiazepine (lorazepam). Red circles = cannabis (Bedrocan). Black oval = drug sober baseline (95% of collected data inside the oval).

    Article Snippet: Next, subjects visited the research unit after fasting for at least 6 h. During this visit, subjects were administered drugs in the form of one of four medicinal products: oxycodone (20 mg oxycodone HCl Teva, oral immediate release), lisdexamphetamine (70 mg Elvanse, oral), lorazepam (2.0 mg Lorazepam Aurobindo, oral) or medicinal cannabis [Bedrocan, Bedrocan International B.V., 65 mg with 22% THC (14.3 mg of which ~5 mg are bioavailable)].

    Techniques: Plasmid Preparation, Cannabis

    (A,B) Plasma concentration of oxycodone and dexamphetamine over time ( n = 12 subjects) and the key feature values for Dbase (z-transformed, from PLR) at sober baseline and 1, 2, 3, 4, and 5 h after drug administration. Ambient illumination was ~50 lux in a and 500 Lux in (B) . (C) Blood concentration of lorazepam over time ( n = 12 subjects) and key feature values for NCdiff (z-transformed, from NC, 50 Lux). (D) Blood concentration of THC over time ( n = 12 subjects) and the key feature values for MCA (z-transformed, from PLR, 50 lux).

    Journal: Frontiers in Neuroscience

    Article Title: Eye reactions under the influence of drugs of abuse as measured by smartphones: a controlled clinical study in healthy volunteers

    doi: 10.3389/fnins.2024.1492246

    Figure Lengend Snippet: (A,B) Plasma concentration of oxycodone and dexamphetamine over time ( n = 12 subjects) and the key feature values for Dbase (z-transformed, from PLR) at sober baseline and 1, 2, 3, 4, and 5 h after drug administration. Ambient illumination was ~50 lux in a and 500 Lux in (B) . (C) Blood concentration of lorazepam over time ( n = 12 subjects) and key feature values for NCdiff (z-transformed, from NC, 50 Lux). (D) Blood concentration of THC over time ( n = 12 subjects) and the key feature values for MCA (z-transformed, from PLR, 50 lux).

    Article Snippet: Next, subjects visited the research unit after fasting for at least 6 h. During this visit, subjects were administered drugs in the form of one of four medicinal products: oxycodone (20 mg oxycodone HCl Teva, oral immediate release), lisdexamphetamine (70 mg Elvanse, oral), lorazepam (2.0 mg Lorazepam Aurobindo, oral) or medicinal cannabis [Bedrocan, Bedrocan International B.V., 65 mg with 22% THC (14.3 mg of which ~5 mg are bioavailable)].

    Techniques: Clinical Proteomics, Concentration Assay, Transformation Assay